Studies reporting on derivation and external validation of models originally not specific to the prognosis or the domain of PE (type 2 model studies), and studies reporting on hospital criteria checklists (type 3 model studies)
| Risk cut-off (author, year) | Development phase | N studies | Type of study | Haemodynamic status | Outcome | Time point | Proportion (95% CI) High-risk group Low-risk group | Event rate(95% CI) High-risk group Low-risk group |
|---|---|---|---|---|---|---|---|---|
| RGS | ||||||||
| (Bertoletti et al 2013)73 | External validation | 1 | Prospective for RGS | Not reported | All-cause death | 3 months | ||
| RGS high | 11.8 (8.8 to 15.5) 88.2 (84.5 to 91.2) | 14.3 (6.6 to 28.3) 4.8 (2.9 to 7.7) | ||||||
| RGS high–intermediate | 84.0 (79.9 to 87.5) 16.0 (12.5 to 20.1) | 7.0 (4.6 to 10.5) 0.9 (0.1 to 12.3) | ||||||
| SGS | ||||||||
| (Bertoletti et al 2013)73 | External validation | 1 | Retrospective for SGS | Not reported | All-cause death | 3 months | ||
| SGS high | 7.8 (5.5 to 11.1) 92.2 (88.9 to 94.5) | 17.9 (7.6 to 36.4) 4.9 (3.0 to 7.8) | ||||||
| SGS high–intermediate | 84.0 (79.9 to 87.5) 16.0 (12.5 to 20.1) | 7.0 (4.6 to 10.5) 0.9 (0.1 to 12.3) | ||||||
| GRACE—ACS risk score | ||||||||
| (Paiva et al 2013)103 | External validation | 1 | Retrospective | Both stable and unstable | All-cause death | 30 days | ||
| GRACE—ACS high | 56.8 (49.9 to 63.4) 43.2 (36.6 to 50.1) | 25.6 (18.5 to 34.3) 10.1 (5.3 to 18.3) | ||||||
| GRACE—ACS high–intermediate | 81.1 (75.1 to 85.9) 18.9 (14.1 to 24.9) | 23.4 (17.6 to 30.4) 1.3 (0.1 to 17.1) | ||||||
| GRACE—PE risk score | ||||||||
| (Paiva et al 2013)103 | External validation | 1 | Retrospective | Both stable and unstable | All-cause death | 30 days | ||
| GRACE—PE high | 49.0 (42.3 to 55.8) 51.0 (44.2 to 57.7) | 29.7 (21.6 to 39.3) 8.6 (4.5 to 15.7) | ||||||
| GRACE—PE high–intermediate | 78.2 (72.0 to 83.3) 21.8 (16.7 to 28.0) | 24.2 (18.2 to 31.4) 1.1 (0.1 to 15.1) | ||||||
| Davies checklist | ||||||||
| (Davies et al 2007)79 | Derivation | 1 | Prospective | Not reported | All-cause death | 3 months | ||
| Unsuitable vs suitable | 57.9 (51.0 to 64.5) 42.1 (35.5 to 49.0) | 5.1 (2.3 to 10.9) 3.5 (1.1 to 10.4) | ||||||
| Davies checklist | ||||||||
| (Davies et al 2007)79 | External validation and impact (management study) | 1 | Prospective | Stable meeting inclusion criteria (suitable) for home treatment | All-cause death | 3 months | Not reported | 1.9 (0.4 to 5.5) |
| PE-related | None | |||||||
| VTE | None | |||||||
| Major/fatal bleeding | None | |||||||
| Hestia checklist | ||||||||
| (Zondag et al 2013)125 | External validation | 1 | Prospective | Both stable and unstable | All-cause death | 30 days | 46.9 (42.4 to 51.4) 53.1 (48.6 to 57.6) | 4.1 (2.2 to 7.7) 0.8 (0.2 to 3.2) |
| 3 months | 46.9 (42.4 to 51.4) 53.1 (48.6 to 57.6) | 9.6 (6.4 to 14.3) 1.2 (0.4 to 3.7) | ||||||
| 7 days | 46.9 (42.4 to 51.4) 53.1 (48.6 to 57.6) | 1.8 (0.7 to 4.8) 0.2 (0.0 to 3.1) | ||||||
| Hestia checklist | ||||||||
| (Zondag et al 2013)126 | External validation (and update) | 1 | Prospective | Both stable and unstable | All-cause death | 30 days | 44.6 (40.2 to 49.0) 55.4 (51.0 to 59.8) | 4.1 (2.1 to 7.6) 0.7 (0.2 to 2.9) |
| Both stable and unstable | Death adverse outcome | 30 days | 44.6 (40.2 to 49.0) 55.4 (51.0 to 59.8) | 19.9 (15.2 to 25.7) 0.7 (0.2 to 2.9) | ||||
| Stable | All-cause death | 30 days | 41.5 (37.1 to 46.0) 58.5 (54.0 to 62.9) | 3.6 (1.7 to 7.3) 0.7 (0.2 to 2.9) | ||||
| Stable | Death adverse outcome | 30 days | 41.5 (37.1 to 46.0) 58.5 (54.0 to 62.9) | 10.3 (6.7 to 15.4) 0.7 (0.2 to 2.9) | ||||
ACS, acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; PE, pulmonary embolism; RGS, revised Geneva score; SGS, simplified Geneva score; VTE, venous thromboembolism.